One‐year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent

Shiratori, Yoshitaka; Brugaletta, Salvatore; Álvarez-Contreras, Luis; Azpeitia, Yajaziel; Ospino, N; Gaido, Sebastian; Delahanty, Anuar; Santos, Alejandro; Martín-Yuste, Victoria; Masotti, Mónica; Serruys, Patrick W.; Windecker, Stephan; Sabaté, Manel

doi:10.1002/ccd.24897

Cited by 7 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, newer DES strive to improve vascular healing while inhibiting the physiological repair processes that are common to any foreign implant . The use of a reservoir on a stent along with a biodegradable polymer is appealing as strategy to combat ST because this construction is expected to minimize vessel wall inflammation. The FIREHAWK® (MicroPort Medical, Shanghai, China) biodegradable polymer sirolimus‐eluting stent (SES) is a novel abluminal groove‐filled biodegradable poly‐lactic acid (PLA) polymer DES with specific targeting of sirolimus release.…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of a novel abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent for the treatment of de novo coronary lesions: Two‐year results from a prospective patient‐level pooled analysis of TARGET trials

Gao

Zhang

et al. 2015

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of a novel abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent for the treatment of de novo coronary lesions: Two‐year results from a prospective patient‐level pooled analysis of TARGET trials

Gao

Zhang

et al. 2015

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…These results should be, therefore, taken into account for future stent design, because polymer-free products are still in development. In light of our data, new drugs, whose elution from the stent platform is not much dependent on a polymer or reservoir technology, 12,13,36 could probably still represent 2 interesting fields of innovation in PF-DES development.…”

Section: Discussionmentioning

confidence: 83%

Randomized Comparison Between Polymer-Free Versus Polymer-Based Paclitaxel-Eluting Stent

Shiratori

Cola

Brugaletta

et al. 2014

Circ: Cardiovascular Interventions

Self Cite

View full text Add to dashboard Cite

Background— Most drug-eluting stents currently in use are coated with a polymer carrying the drug that is released for several weeks. However, a durable polymer may provoke hypersensitive reaction, delayed artery healing, and eventually stent thrombosis. The aim of this study was to investigate the safety and efficacy of a polymer-free paclitaxel-eluting stent (PF-PES) versus a polymer-based PES (PB-PES). Methods and Results— Eligible patients undergoing percutaneous coronary intervention were randomized 1:1 to receive either PF-PES or PB-PES. The primary end point was late loss at 9 months. Intravascular ultrasound analysis at 9 months and final 2-year clinical follow-up were also performed. From October 2007 to April 2009, 164 patients were enrolled and randomized into 2 groups (PF-PES: n=84; PB-PES: n=80). Mean in-stent lumen loss was 0.90±0.59 mm for PF-PES and 0.49±0.52 mm for PB-PES ( P <0.001). Mean neointimal area by intravascular ultrasound was higher in PF-PES than in PB-PES (1.42±1.09 versus 0.51±0.61 mm 2 ; P <0.001). At 2 years, a composite end point of all-cause death, any myocardial infarction, and target vessel revascularization occurred in 36.9% for PF-PES and 16.3% for PB-PES ( P =0.004), mainly driven by a higher rate of target vessel revascularization (PF-PES: 35.7%; PB-PES: 13.8%; P =0.001). One late stent thrombosis was observed in PF-PES. Conclusions— Compared with PB-PES, PF-PES was associated with increased neointimal proliferation and subsequent clinical restenosis. Polymer plays an essential role in the performance of drug-eluting stents. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01375855.

show abstract

“…Previous OCT studies indicated an increase in the neointimal volume in durable polymer sirolimus eluting stents and BP-DES from 6 to 12 months post implantation [17,18]. Nonetheless, the differences were small and did not affect the strut coverage.…”

Section: Discussionmentioning

confidence: 88%

An optical coherence tomography study of neointimal morphology and strut coverage at different time intervals from implantation of biodegradable polymer‐coated sirolimus‐eluting stents

Legutko

Gil²,

Kałuża

et al. 2017

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

One‐year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent

Abstract: The NEVO stent with a reservoir technology seems to exhibit more neointimal proliferation as compared to Xience stent. The findings of our study, which currently represent the unique data existing on this reservoir technology, would need to be confirmed in a large population.

Cited by 7 publications

References 27 publications

Safety and efficacy of a novel abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent for the treatment of de novo coronary lesions: Two‐year results from a prospective patient‐level pooled analysis of TARGET trials

Safety and efficacy of a novel abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent for the treatment of de novo coronary lesions: Two‐year results from a prospective patient‐level pooled analysis of TARGET trials

Randomized Comparison Between Polymer-Free Versus Polymer-Based Paclitaxel-Eluting Stent

An optical coherence tomography study of neointimal morphology and strut coverage at different time intervals from implantation of biodegradable polymer‐coated sirolimus‐eluting stents

Contact Info

Product

Resources

About